甘精胰岛素联合格列吡嗪控释片治疗2型糖尿病有效性和安全性研究

Safety and efficacy of glargine combined with glipizide extended-release tablets in the treatment of type II diabetic patients

目的评价甘精胰岛素(商品名长秀霖)联合格列吡嗪控释片(瑞易宁)治疗口服降糖药血糖控制不佳的2型糖尿病的有效性和安全性。方法共选择40例2型糖尿病患者随机分为2组,对照组10例,给予诺和灵N皮下注射与瑞易宁口服;试验组30例,给予甘精胰岛素皮下注射与瑞易宁口服,疗程12周。结果12周后,40例患者HbAlc和空腹血糖达标水平分别为<7．5％和≤6．7 mmol／L, 2组间HbAlc、空腹血糖和HbAlc+空腹血糖的达标率无差异(P>0．05),低血糖和夜间低血糖的受试者例数相当,无严重低血糖事件,BMI平均增加0．43和0．66,两组间无差异(P>0．05),两组治疗前后收缩压、舒张压及静息心率无明显改变。结论甘精胰岛素和诺和灵N分别与格列吡嗪控释片联合应用疗效相当,且具有良好的耐受性。

Objective To evaluate the safety and efficacy of glargine （Changxiulin） combined with glipizide extended-release tablets in the treatment of type Ⅱ diabetic patients whose glycemia could not be controlled by oral antidiabetic drug. Methods 40 type 2 diabetic patients were selected and randomized into two groups. 30 patients were treated with glargine combined with glipizide extended-release tablets, and 10 patients with Novolin N combined with glipizide extended-release tablets. Results Compared with the baseline, the levels of HbAlc and fasting plasma glucose in the two groups in 12 weeks showed no significant difference （P 〉0, 05 ）. Cases of hypoglycaemia were resemble between the two groups, and no serious hypoglycaemia event was found. BMI increased by 0.43 - 0.66 on average. No obvious changes in BP and resting heart rate were found after treatments in both groups. Conclusions Glargine combined with glipizide extended-release tablets was safe and effective in treating type 2 diabetic patients.